193 related articles for article (PubMed ID: 15857976)
1. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Martinez-Picado J; Wrin T; Frost SD; Clotet B; Ruiz L; Brown AJ; Petropoulos CJ; Parkin NT
J Virol; 2005 May; 79(10):5907-13. PubMed ID: 15857976
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
[TBL] [Abstract][Full Text] [Related]
4. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
Leigh Brown AJ; Frost SD; Good B; Daar ES; Simon V; Markowitz M; Collier AC; Connick E; Conway B; Margolick JB; Routy JP; Corbeil J; Hellmann NS; Richman DD; Little SJ
J Virol; 2004 Mar; 78(5):2242-6. PubMed ID: 14963120
[TBL] [Abstract][Full Text] [Related]
5. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.
Barbour JD; Wrin T; Grant RM; Martin JN; Segal MR; Petropoulos CJ; Deeks SG
J Virol; 2002 Nov; 76(21):11104-12. PubMed ID: 12368352
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
7. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
[TBL] [Abstract][Full Text] [Related]
9. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Ziermann R; Limoli K; Das K; Arnold E; Petropoulos CJ; Parkin NT
J Virol; 2000 May; 74(9):4414-9. PubMed ID: 10756056
[TBL] [Abstract][Full Text] [Related]
10. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
Martinez-Picado J; Savara AV; Shi L; Sutton L; D'Aquila RT
Virology; 2000 Sep; 275(2):318-22. PubMed ID: 10998332
[TBL] [Abstract][Full Text] [Related]
11. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Kemper CA; Witt MD; Keiser PH; Dubé MP; Forthal DN; Leibowitz M; Smith DS; Rigby A; Hellmann NS; Lie YS; Leedom J; Richman D; McCutchan JA; Haubrich R;
AIDS; 2001 Mar; 15(5):609-15. PubMed ID: 11316998
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
[TBL] [Abstract][Full Text] [Related]
13. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.
Servais J; Hainaut M; Schmitz V; Maes P; Fransen K; Vaira D; Brichard B; Arendt V; Schneider F; Hemmer R; Schmit JC
Pediatr Infect Dis J; 2002 Mar; 21(3):214-20. PubMed ID: 12005085
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
15. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
16. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
17. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
18. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
[TBL] [Abstract][Full Text] [Related]
20. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
